Back to Search Start Over

Sports doping: emerging designer and therapeutic β2-agonists.

Authors :
Fragkaki AG
Georgakopoulos C
Sterk S
Nielen MW
Source :
Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2013 Oct 21; Vol. 425, pp. 242-58. Date of Electronic Publication: 2013 Aug 14.
Publication Year :
2013

Abstract

Beta2-adrenergic agonists, or β2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel β2-agonists molecules either by modifying the molecule of known β2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.<br /> (© 2013.)

Details

Language :
English
ISSN :
1873-3492
Volume :
425
Database :
MEDLINE
Journal :
Clinica chimica acta; international journal of clinical chemistry
Publication Type :
Academic Journal
Accession number :
23954776
Full Text :
https://doi.org/10.1016/j.cca.2013.07.031